Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 15Breast 15Gastrointestinal 14Thoracic 6Head & Neck 6Endocrine 6Genitourinary 4Tumor-Agnostic 3Other 2Sarcoma 1Other solid neoplasm 1Other neoplasm 1

Conditions

Intrathecal Dexmedetomidine 1

Interventions

Surveys and Questionnaires 9Cyclophosphamide 9Whole-Body Irradiation 7Biopsy 7fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 6Educational Status 6Early Intervention, Educational 6Busulfan 6Methotrexate 5Methods 5Immunohistochemistry 5Epoetin Alfa 5Tacrolimus 4Mycophenolic Acid 4Interviews as Topic 4Gene Expression Profiling 4Decitabine 4Cyclosporine 4Celecoxib 4Antilymphocyte Serum 4fludarabine 3Sirolimus 3Radiotherapy 3Paclitaxel 3Microarray Analysis 3Melphalan 3Magnetic Resonance Spectroscopy 3Imiquimod 3Fentanyl 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Dexmedetomidine × Other neoplasm × Clear all
NCT02861716 2018-04-10

Intrathecal Dexmedetomidine Versus Fentanyl With Bupivacaine in Children Undergoing Major Abdominal Cancer Surgery

South Egypt Cancer Institute

Phase 2 Unknown
60 enrolled
Other neoplasm

Intrathecal Dexmedetomidine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡